Candidiasis – Pipeline Review, H2 2018

Global Markets Direct’s, ‘Candidiasis – Pipeline Review, H2 2018’, provides an overview of the Candidiasis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Candidiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Candidiasis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Candidiasis

– The report reviews pipeline therapeutics for Candidiasis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Candidiasis therapeutics and enlists all their major and minor projects

– The report assesses Candidiasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Candidiasis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Candidiasis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Candidiasis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Amplyx Pharmaceuticals Inc

APEIRON Biologics AG

Bakker Medical Srl

Beta Pharma Inc

Bionex Pharmaceuticals LLC

Biosergen AS

Cellix Bio Pvt Ltd

Cidara Therapeutics Inc

General Biologicals Corp

Grupo Ferrer Internacional SA

Helix BioMedix Inc

iCo Therapeutics Inc

Matinas BioPharma Holdings Inc

Nanomerics Ltd

Nosopharm SAS

Novabiotics Ltd

NovaDigm Therapeutics Inc

Novartis AG

Onxeo SA

Pulmocide Ltd

Scynexis Inc

Sealife PHARMA GMBH

Viamet Pharmaceuticals Inc

Visterra Inc

Wellstat Vaccines LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Candidiasis Overview

Candidiasis Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Candidiasis Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Candidiasis Companies Involved in Therapeutics Development

Amplyx Pharmaceuticals Inc

APEIRON Biologics AG

Bakker Medical Srl

Beta Pharma Inc

Bionex Pharmaceuticals LLC

Biosergen AS

Cellix Bio Pvt Ltd

Cidara Therapeutics Inc

General Biologicals Corp

Grupo Ferrer Internacional SA

Helix BioMedix Inc

iCo Therapeutics Inc

Matinas BioPharma Holdings Inc

Nanomerics Ltd

Nosopharm SAS

Novabiotics Ltd

NovaDigm Therapeutics Inc

Novartis AG

Onxeo SA

Pulmocide Ltd

Scynexis Inc

Sealife PHARMA GMBH

Viamet Pharmaceuticals Inc

Visterra Inc

Wellstat Vaccines LLC

Candidiasis Drug Profiles

(clotrimazole + diclofenac sodium) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

61894700 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AC-17 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amphotericin B Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Amphotericin B sodium Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibody to Target Ece1 for Candidiasis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APX-001 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APX-001A Drug Profile

Product Description

Mechanism Of Action

R&D Progress

arasertaconazole nitrate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BL-5923 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BSG-005 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

candidiasis vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Fungal Infections Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellullar Immunotherapy for Viral Infections and Fungal Infections Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLX-159 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLX-1593 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CSA-13 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug for Oral Candidiasis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Forazoline A Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HB-1345 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HCP-002 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ibrexafungerp Drug Profile

Product Description

Mechanism Of Action

R&D Progress

iCo-010 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

iCo-019 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

iCo-022 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JSM-11 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KSL-W Drug Profile

Product Description

Mechanism Of Action

R&D Progress

miconazole nitrate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies for Candidiasis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody for Candidiasis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mutanobactin A Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MYC-053 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Myc-102 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NDV-3 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NDV-3A Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOSO-F2 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NP-339 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

obliquumol Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Occidiofungin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-113 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-113Du Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-113Tri Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PC-1244 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Polymers for Clostridium difficile Infections and Candidiasis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Prof-002 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Peptide for Candidiasis and Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Peptides for Oropharyngeal Candidiasis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for Infectious Diseases Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rezafungin acetate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SLP-0901 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SLP-0904 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Bacterial Vaginosis and Candidiasis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Candidiasis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Candidiasis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Fungal Infections Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Systemic Candidiasis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit CBL-B for Candidiasis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides for Candidiasis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides for Infectious Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TOL-463 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Ece1 for Candidiasis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Glucosylceramide for Fungal Infections Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VIS-FNG Drug Profile

Product Description

Mechanism Of Action

R&D Progress

voriconazole Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VT-1129 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VT-1161 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VT-1598 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Candidiasis Dormant Projects

Candidiasis Discontinued Products

Candidiasis Product Development Milestones

Featured News & Press Releases

Jul 18, 2018: The World Health Organization Recognizes New Antifungal Class by Granting "ibrexafungerp" to SCYNEXIS as the International Non-Proprietary Name for SCY-078

Jul 10, 2018: SCYNEXIS Reports Positive Results from Phase 2b Dose-Finding Study of Oral SCY-078 in Vulvovaginal Candidiasis

Jun 27, 2018: SCYNEXIS Announces the Presentation of SCY-078 Data at the Teratology Society 58th Annual Meeting

Jun 14, 2018: SCYNEXIS to Present SCY-078 Data at Three Scientific Meetings in June/July 2018

Jun 11, 2018: SCYNEXIS Presents SCY-078 Data at ASM Microbe 2018

Jun 06, 2018: Matinas BioPharma to Present Preclinical Data of Candidiasis Drug Candidate MAT2203 at ASM Microbe 2018

Jun 06, 2018: SCYNEXIS Announces the Publication of Phase 1 Study Results for SCY-078 in The Journal of Clinical Pharmacology

May 24, 2018: SCYNEXIS to Present SCY-078 Data at ASM Microbe 2018

May 23, 2018: Data to be Presented at ASM Microbe 2018 Demonstrate the Efficacy and Safety of Cidara s Rezafungin for the Treatment of Invasive Fungal Infections

May 01, 2018: SCYNEXIS's Oral SCY-078 Receives FDA QIDP and Fast Track Designations for the Treatment of VVC and Prevention of Recurrent VVC

Apr 30, 2018: Amplyx Pharmaceuticals Demonstrates APX001 has Potent Activity Against Deadly Multidrug-Resistant Candida Species

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Candidiasis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Products under Development by Universities/Institutes, H2 2018

Products under Development by Universities/Institutes, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Candidiasis Pipeline by Amplyx Pharmaceuticals Inc, H2 2018

Candidiasis Pipeline by APEIRON Biologics AG, H2 2018

Candidiasis Pipeline by Bakker Medical Srl, H2 2018

Candidiasis Pipeline by Beta Pharma Inc, H2 2018

Candidiasis Pipeline by Bionex Pharmaceuticals LLC, H2 2018

Candidiasis Pipeline by Biosergen AS, H2 2018

Candidiasis Pipeline by Cellix Bio Pvt Ltd, H2 2018

Candidiasis Pipeline by Cidara Therapeutics Inc, H2 2018

Candidiasis Pipeline by General Biologicals Corp, H2 2018

Candidiasis Pipeline by Grupo Ferrer Internacional SA, H2 2018

Candidiasis Pipeline by Helix BioMedix Inc, H2 2018

Candidiasis Pipeline by iCo Therapeutics Inc, H2 2018

Candidiasis Pipeline by Matinas BioPharma Holdings Inc, H2 2018

Candidiasis Pipeline by Nanomerics Ltd, H2 2018

Candidiasis Pipeline by Nosopharm SAS, H2 2018

Candidiasis Pipeline by Novabiotics Ltd, H2 2018

Candidiasis Pipeline by NovaDigm Therapeutics Inc, H2 2018

Candidiasis Pipeline by Novartis AG, H2 2018

Candidiasis Pipeline by Onxeo SA, H2 2018

Candidiasis Pipeline by Pulmocide Ltd, H2 2018

Candidiasis Pipeline by Scynexis Inc, H2 2018

Candidiasis Pipeline by Sealife PHARMA GMBH, H2 2018

Candidiasis Pipeline by Viamet Pharmaceuticals Inc, H2 2018

Candidiasis Pipeline by Visterra Inc, H2 2018

Candidiasis Pipeline by Wellstat Vaccines LLC, H2 2018

Candidiasis Dormant Projects, H2 2018

Candidiasis Dormant Projects, H2 2018 (Contd..1), H2 2018

Candidiasis Dormant Projects, H2 2018 (Contd..2), H2 2018

Candidiasis Dormant Projects, H2 2018 (Contd..3), H2 2018

Candidiasis Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Candidiasis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Top 10 Routes of Administration, H2 2018

Number of Products by Stage and Top 10 Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports